These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2890668)

  • 1. The influence of food on the oral absorption of bevantolol.
    Toothaker RD; Randinitis EJ; Nelson C; Kinkel AW; Goulet JR
    J Clin Pharmacol; 1987 Apr; 27(4):297-9. PubMed ID: 2890668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.
    Selen A; Kinkel AW; Darke AC; Greene DS; Welling PG
    Eur J Clin Pharmacol; 1986; 30(6):699-704. PubMed ID: 2876899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevantolol disposition in patients with hepatic cirrhosis.
    Nattel S; Lawand S; Matthews C; McCans J
    J Clin Pharmacol; 1987 Dec; 27(12):962-6. PubMed ID: 2893814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
    Frishman WH; Goldberg RJ; Benfield P
    Drugs; 1988 Jan; 35(1):1-21. PubMed ID: 2894292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and metabolism of bevantolol.
    Latts JR
    Angiology; 1986 Mar; 37(3 Pt 2):221-5. PubMed ID: 2871781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of bevantolol for chronic, stable angina pectoris.
    Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
    Am J Cardiol; 1986 Nov; 58(12):28E-34E. PubMed ID: 2878598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers.
    McNeil JJ; Drummer OH; Anderson AI; Louis WJ
    J Cardiovasc Pharmacol; 1986; 8(6):1201-7. PubMed ID: 2434747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of once and twice daily oral dosing schedules of bevantolol, a new beta-adrenoceptor antagonist with alpha-adrenoceptor partial antagonist activity in patients with angina of effort.
    Molajo AO; Bray CL; Hillier V
    Int J Cardiol; 1989 Nov; 25(2):185-92. PubMed ID: 2572566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
    Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bevantolol and atenolol for systemic hypertension.
    Fairhurst GJ
    Am J Cardiol; 1986 Nov; 58(12):25E-27E. PubMed ID: 2878597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bevantolol and atenolol in chronic stable angina.
    Rodrigues EA; Lawrence JD; Dasgupta P; Hains AD; Lahiri A; Wilkinson PR; Raftery EB
    Am J Cardiol; 1988 Jun; 61(15):1204-9. PubMed ID: 2897780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the respiratory effects of two beta 1-selective blocking agents atenolol and bevantolol in asthmatic patients.
    Philip-Joet F; Saadjian A; Bruguerolle B; Arnaud A
    Eur J Clin Pharmacol; 1986; 30(1):13-6. PubMed ID: 2872059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of bevantolol in the treatment of angina--a placebo-controlled study.
    Farnham DJ
    Angiology; 1986 Mar; 37(3 Pt 2):226-32. PubMed ID: 2871782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
    Solimon M; Massry SG; Campese VM
    Am J Cardiol; 1986 Nov; 58(12):21E-24E. PubMed ID: 2878596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment.
    Cockshott ID
    Drugs; 1989; 38 Suppl 2():10-7. PubMed ID: 2575975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.
    Regardh CG; Heggelund A; Kylberg-Hanssen K; Lundborg P
    Biopharm Drug Dispos; 1990 Oct; 11(7):607-17. PubMed ID: 1979923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma bevantolol concentration and heart rate in rabbits.
    Liu XQ; Ye XL; Zhu HQ; Huang SK
    Zhongguo Yao Li Xue Bao; 1993 May; 14(3):200-2. PubMed ID: 7901961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.